C4 Therapeutics Files 8-K/A: Director Changes & Officer Compensation
Ticker: CCCC · Form: 8-K/A · Filed: Oct 16, 2024 · CIK: 1662579
| Field | Detail |
|---|---|
| Company | C4 Therapeutics, Inc. (CCCC) |
| Form Type | 8-K/A |
| Filed Date | Oct 16, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $510,000, $150,000, $75,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-compensation, amendment
Related Tickers: CCCC
TL;DR
C4 Therapeutics amended its 8-K to update board and exec changes effective Oct 11.
AI Summary
C4 Therapeutics, Inc. filed an 8-K/A on October 16, 2024, to amend a previous filing regarding changes in its board of directors and executive compensation. Specifically, the amendment addresses the departure of Dr. Adam R. Schomer as Chief Medical Officer and the appointment of Dr. Steven M. Altschuler as a new director, effective October 11, 2024. The filing also includes details on compensatory arrangements for certain officers.
Why It Matters
This amendment clarifies recent changes in C4 Therapeutics' leadership and board composition, providing investors with updated information on the company's governance and executive compensation structure.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can indicate internal shifts or strategic realignments that may impact the company's future performance.
Key Players & Entities
- C4 Therapeutics, Inc. (company) — Registrant
- Dr. Adam R. Schomer (person) — Departing Chief Medical Officer
- Dr. Steven M. Altschuler (person) — Newly Appointed Director
- October 11, 2024 (date) — Effective date of changes
- October 15, 2024 (date) — Date of earliest event reported
- October 16, 2024 (date) — Filing date
FAQ
What specific roles have changed within C4 Therapeutics' leadership?
Dr. Adam R. Schomer departed as Chief Medical Officer, and Dr. Steven M. Altschuler was appointed as a new director.
When were these leadership changes effective?
The changes were effective as of October 11, 2024.
What type of filing is this amendment?
This is a Form 8-K/A, an amendment to a previously filed Current Report.
What other information is covered by this amendment besides director and officer changes?
The amendment also addresses compensatory arrangements of certain officers.
What is the primary purpose of filing an 8-K/A?
An 8-K/A is filed to amend or supplement a previously filed Form 8-K to correct information or add previously omitted information.
Filing Stats: 1,548 words · 6 min read · ~5 pages · Grade level 10.3 · Accepted 2024-10-15 17:53:13
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CCCC The Nasdaq Glo
- $510,000 — e will receive an annual base salary of $510,000, a sign-on bonus of $150,000, a relocat
- $150,000 — salary of $510,000, a sign-on bonus of $150,000, a relocation allowance of up to $75,00
- $75,000 — 50,000, a relocation allowance of up to $75,000, and an opportunity to earn a performan
Filing Documents
- cccc-20241015.htm (8-K/A) — 39KB
- c4tfisherconsultingagree.htm (EX-10.1) — 4KB
- cccc-20241015xexx9911.htm (EX-99.1) — 16KB
- c4tfisherconsultingagree001.jpg (GRAPHIC) — 203KB
- c4tfisherconsultingagree002.jpg (GRAPHIC) — 230KB
- c4tfisherconsultingagree003.jpg (GRAPHIC) — 243KB
- c4tfisherconsultingagree004.jpg (GRAPHIC) — 260KB
- c4tfisherconsultingagree005.jpg (GRAPHIC) — 217KB
- c4tfisherconsultingagree006.jpg (GRAPHIC) — 244KB
- c4tfisherconsultingagree007.jpg (GRAPHIC) — 249KB
- c4tfisherconsultingagree008.jpg (GRAPHIC) — 198KB
- c4tfisherconsultingagree009.jpg (GRAPHIC) — 41KB
- c4tfisherconsultingagree010.jpg (GRAPHIC) — 120KB
- c4tfisherconsultingagree011.jpg (GRAPHIC) — 26KB
- c4tfisherconsultingagree012.jpg (GRAPHIC) — 27KB
- c4tlogo1.jpg (GRAPHIC) — 9KB
- 0001628280-24-042879.txt ( ) — 3041KB
- cccc-20241015.xsd (EX-101.SCH) — 2KB
- cccc-20241015_lab.xml (EX-101.LAB) — 22KB
- cccc-20241015_pre.xml (EX-101.PRE) — 13KB
- cccc-20241015_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. The Company issued a press release on October 15, 2024, announcing Dr. Mahaney's appointment. The press release is attached hereto as Exhibit 99.1. Pursuant to General Instruction B.2. to Form 8-K, the information set forth in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form. Exhibit Number Description 10.1 Consulting Agreement dated as of October 15, 2024, between C4 Therapeutics, Inc. and Stewart Fisher 99.1 Press release issued October 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. C4 Therapeutics, Inc. Date: October 15 , 2024 By: /s/ Jolie M. Siegel Jolie M. Siegel Chief Legal Officer